Novocure (NSDQ:NVCR) today released results from the Stellar phase 2 registration trial exploring the use of its Tumor Treating Fields and standard of care chemotherapy to chemotherapy alone in treating mesothelioma, touting a significant extension in median overall survival.
Patients with malignant pleural mesothelioma who received TTF treatment alongside pemetrexed and cisplatin or carboplatin experienced a median overall survival of 18.2 months, compared to 12.1 months in a historical control, the St. Helier, Jersey-based company said.
Read the whole story on our sister site, Drug Delivery Business News